

## Mutation and Polymorphism Report

**Authors:** Nisrine Bissar-Tadmouri, Yesim Gulsen-Parman, Philippe Latour, Feza Deymeer, Piraye Serdaroglu, Antoon Vandenbergh, and Esra Battaloglu.

**Affiliations:** *Bogazici University, Department of Molecular Biology and Genetics, Istanbul University Medical School, Department of Neurology; Laboratoire de Neurogenetique Moleculaire, Hopital de l'Antiquaille, Faculte de Pharmacie, Universite Claude Bernard Lyon 1.*

**Corresponding Author Address and E-mail:** Esra Battaloglu, Bogazici University, Department of Molecular Biology and genetics, 80815 Bebek, Istanbul, Turkey. Fax: +90 212 2659778, tel +90 212 2631540/1883, email: [battalog@boun.edu.tr](mailto:battalog@boun.edu.tr)

**Title :** Two novel mutations in the MPZ gene coding region in Charcot-Marie-Tooth type 1 patients of Turkish origin: S54P, [I30del; GVIYI29ins]

**Keywords:** Two Charcot-Marie-Tooth type 1B, CMT1B, myelin protein zero, MPZ, Turkey

**Species:** Homo sapiens

**Change is:** One point mutation, and one deletion/insertion

### Gene/Locus

**Name:** Myelin Protein Zero  
**Symbol:** MPZ  
**Genbank accession number:** D14584  
**OMIM accession number:** 118200  
**Locus specific database:**  
**Chromosomal location:** 1q22-q23  
**Inheritance:** Somatic- Autosomal Dominant

### Mutation / polymorphism name

**Nucleotide change–Systematic name:** 1) g161T>C  
 2) g89-91delATC, g88-92ins GGGGTTTACACC

**Amino acid change–Trivial name:** 1) S54P  
 2) I30del; GVIYI29ins

**Mutation / polymorphism type:** Missense, Deletion-Insertion

**Polymorphism frequency:**

**Detection method:** SSCP and DNA Sequencing

**Detection conditions:** As described by Nelis et al. 1994.

**Diagnosis method developed:** 1) Hae III restriction analysis for S54P; 2) I30del; GVIYI29ins mutation cloning and sequencing were performed

**Evidence for existence and effect of mutation:**

	Yes	No	Don't know
1. Base change found on repeat PCR sample	1)x		
	2)cloned		
2. Base change segregates or appears with trait	xx		
3. Base change affects conserved residue	xx		
4. Expression analysis supports hypothesis for causation			xx
5. Normals tested (50 required)	xx		

**Ancillary data**1. **Haplotype association :**2. **Ethnic background/Population association :** Turkish population3. **Geographic association :**4. **Frequency (of mutation) in population:**5. **Clinical phenotype of proband :**

Patient 1: distal weakness, abolished deep tendon reflexes, and diminished vibratory sensation in the lower extremities, pes cavus and hammer toes. Absence of sensory action potential, median motor NCV was 22m/s.

Patient 2: distal weakness and wasting of the extremities, areflexia, glove and stocking type of hypoesthesia with diminished vibratory sensation of the four limbs, and pes cavus. Absence of sensory action potentials, NCV of median nerve was 17m/s.

Both patients: severe reduction in density of myelinated fibers with onion bulbs on sural nerve biopsy.

6. **Homologous allele (if recessive trait):**7. **PIC:** (if microsatellite)8. **Other:**9. **Present in HGMD listing:**

(<http://www.cf.ac.uk/uwcm/mg/hgmd0.html>)

Yes:      No:  
             xx

**Comments**

Charcot-Marie-Tooth type 1B (CMT1B) cosegregates with mutations in the Myelin Protein Zero (MPZ) gene (Pham-Dinh et al, 1993). MPZ functions as a double adhesion molecule to hold together the myelin sheath through extracellular and cytoplasmic interactions (Fiblin et al, 1990). In this study, we report MPZ gene mutations in exon 2 of two unrelated CMT1B patients from Turkey. Both patients were clinically diagnosed as CMT1 with NCV values of 22 and 17m/s. Patient 1 is a 26-year old female with no family history of neurological disorders. The patient was found to be heterozygous for a T>C transition resulting in a S54P substitution. This mutation creates a *Hae* III restriction site which was detected in the patient but not in her parents and 50 normal controls. Introduction of Proline by this substitution might result in an extra  $\alpha$  helix in the amino acid chain, and therefore alter the capacity of the extracellular domain to interact correctly. Patient 2 is a 57-year old diabetic male. His mother and maternal grandmother had complained of unstable walking prior to their death. In patient 2, sequencing of the cloned exon 2 fragment revealed the deletion of codon 30 and an insertion of 12 nucleotides which seems to be an imperfect (GTG -> GGG at codon 31) tandem duplication of the following 12 nucleotides. While Isoleucine at codon 30 has been deleted, Glycine, Valine, Tyrosine, and Threonine have been

inserted in its place. This mutation will lengthen the beta strand between Isoleucine 30 and the following 5 amino acids (Kirschner et al, 1994), and may hinder normal homophilic interactions. The two novel mutations reported here, in addition to others, will help unravel underlying molecular mechanisms that lead to CMT1.

### Acknowledgments

This work was supported by grants from Bogazici University Research Fund, Association Française contre les Myopathies (AFM), and the Hospices Civils de Lyon. The laboratory of Molecular Neurogenetics is a member of the European CMT Consortium sponsored by the EU Biomed and grants CT961614 and CT 960055. Nisrine Bissar-Tadmouri is a TUBITAK fellow.

### References

- Fiblin MT, Walsh FS, Trapp BD, Pizzey JA, Tennekoon GI. 1990. Role of myelin P<sub>0</sub> protein as a homophilic adhesion molecule. *Nature* 344: 871-872.
- Kirschner DA and Saavedra RA. 1994. Mutations in demyelinating peripheral neuropathies support molecular model of myelin P<sub>0</sub>-glycoprotein extracellular domain. *J Neurosci Res* 39: 63-69.
- Nelis E, Timmerman V, De Jonghe P, vandenbergh A, Pham Dinh D, Dautigny A, Martin J-J, van Broeckhoven C. 1994. Rapid screening of myelin genes in CMT1 patients by SSCP analysis: Identification of new mutations and polymorphisms in the P<sub>0</sub> gene. *Hum Genet* 94: 653-657.
- Pham-Dinh D, Fourbil Y, Blanquet F, Mattei MG, Roeckel N, Latour P, Chazot G, vandenbergh A, Dautigny A. 1993. The major peripheral myelin protein zero gene: Structure and localization in the cluster of Fcγ receptor genes on human chromosome 1q21.3-q23. *Hum Mol Genet* 2: 2051-2054.

